Skip to main content
. 2020 Jun 1;10(6):65. doi: 10.1038/s41408-020-0331-4

Fig. 6. VLA4 inhibition reverses stromal-mediated immune-suppression and protection of tumor cells from CD3 redirected cytotoxicity in vivo.

Fig. 6

AML cell line MOLM-13 and MOLM-13 with HS-5 bone marrow stromal cells (5:1) were implanted sc in huPBMC injected female NSG mice on study day 0. Mice were treated with CD123xCD3 (8 μg/kg) either alone or in combination with a neutralizing antibody against VLA4 (3 mg/kg). PBS-treated groups were included as controls. a Mean tumor volume measurements for all the groups at different time points. b Analysis of activation, effector, and checkpoint inhibition markers in CD8+ T cells in the tumors of mice on day 23. All data shown are representative of two independent experiments and are represented as mean ± SEM (a) and median with range (b). ∗p < 0.05, ∗∗p < 0.005, ∗∗∗p < 0.0005; ∗∗∗∗p < 0.0001; n.s. not statistically significant.